<DOC>
	<DOCNO>NCT00157885</DOCNO>
	<brief_summary>The primary aim comparative trial ass relative safety efficacy two artemisinin contain regimen : amodiaquine plus artesunate ( AAQ ) artekin administer daily 3 day .</brief_summary>
	<brief_title>A Randomised Trial Artekin Artesunate &amp; Amodiaquine Uncomplicated Malaria Timika , Papua , Indonesia .</brief_title>
	<detailed_description>With emergence specie multi drug resistant P.falciparum across archipelago Indonesian Centre Disease Control ( CDC ) recommend amodiaquine plus artesunate area high chloroquine sulfadoxine-pyrimethamine resistant strain P. falciparum . High level chloroquine resistance P.vivax also emerge eastern province . This trial set assess efficacy artekin amodiaquine plus artesunate artekin P.falciparum P. vivax . safety profile . Patients present establish rural outpatient clinic Timika , Papua symptoms acute , uncomplicated infection P. falciparum , P.vivax specie , laboratory confirmation diagnosis give informed consent participate trial , enrol study . Patients treat out-patients see daily first week aparasitaemic thereafter weekly visit clinic . The data use trial use make public health decision determine suitable alternative first line antimalarial Timika region . In order ensure data gather relevant clinical setting drug use , drug administration medication deliberately design mimic condition experience widespread deployment ( eg daily supervision ) .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Male female patient least one 1year age weigh 5kg . Microscopic confirmation P. falciparum /or P.vivax infection ( parasitaemia ) . Fever ( axillary temperature &gt; 37.5oC ) history fever last 48 hour . Able participate trial comply clinical trial protocol Written inform consent participate trial ; verbal consent presence literate witness require illiterate patient , write consent parents/guardian child age consent Pregnancy lactation Inability tolerate oral treatment Signs/symptoms indicative severe/complicated malaria warn sign require parenteral treatment Known hypersensitivity allergy artemisinin derivative Serious underlying disease ( cardiac , renal hepatic ) Parasitaemia &gt; 4 %</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Falciparum</keyword>
	<keyword>Vivax</keyword>
	<keyword>Papua</keyword>
	<keyword>Amodiaquine</keyword>
	<keyword>Artekin</keyword>
	<keyword>Artemisinin Combination Therapy</keyword>
	<keyword>Dihydroartemisinin</keyword>
	<keyword>Piperaquine</keyword>
	<keyword>Lumefantrine</keyword>
	<keyword>Artemether</keyword>
</DOC>